SCHEMBL14979290

SCHEMBL14979290

CCOC(=O)[C@@]1(CO)C[C@@H]1CO

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.34
ALDH1A1 P00352 2/20 0.33
OPRM1 P35372 1/20 0.33
ADAM17 P78536 1/20 0.33
LMNA P02545 3/20 0.33
ATM Q13315 1/20 0.33
HSD17B10 Q99714 1/20 0.32
ALOX15 P16050 2/20 0.31
MGAM O43451 1/20 0.31
GAA P10253 1/20 0.31
SI P14410 1/20 0.31
MGAM2 Q2M2H8 1/20 0.31
SOAT1 P35610 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
KDM4E B2RXH2 2/20 0.31
MAPK1 P28482 1/20 0.31
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7513123 1.00 POLB (0.34) POLBALDH1A1OPRM1ADAM17LMNA
SCHEMBL13537384 1.00 POLB (0.34) POLBALDH1A1OPRM1ADAM17LMNA
SCHEMBL17462342 0.83 POLB (0.31) POLBADAM17
SCHEMBL12057961 0.77 POLB (0.36) POLBALDH1A1OPRM1LMNAATM
SCHEMBL30706721 0.77 POLB (0.36) POLBALDH1A1OPRM1LMNAATM
SCHEMBL15337099 0.76 F10 (0.37) POLBALDH1A1OPRM1LMNAATM
SCHEMBL15927850 0.76 POLB (0.35) POLBALDH1A1ADAM17LMNAATM
SCHEMBL15927852 0.76 POLB (0.35) POLBALDH1A1ADAM17LMNAATM
SCHEMBL1041202 0.74 POLB (0.34) POLBALDH1A1OPRM1LMNAATM
SCHEMBL20107360 0.74 POLB (0.32) POLBALDH1A1OPRM1ADAM17LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236608-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-07-24 US disclosed
EP-4504719-A1 EGFR INHIBITORS Blueprint Medicines Corporation (US) 2025-02-12 EP disclosed
CN-119325471-A EGFR inhibitors 缆图药品公司 2025-01-17 CN disclosed
WO-2023196283-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2023-10-12 WO disclosed
WO-2013072825-A1 PHTALAZINONE DERIVATIVES AS MPEGS -1 INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250236608-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 POLB 2916/4885ALDH1A1 2147/4885OPRM1 3452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.